Skip to Content
Merck
  • Mometasone furoate dry-powder inhaler for the control of persistent asthma.

Mometasone furoate dry-powder inhaler for the control of persistent asthma.

Expert opinion on pharmacotherapy (2007-10-25)
Anthony D'Urzo
ABSTRACT

Mometasone furoate dry-powder inhaler (MF-DPI) is an inhaled corticosteroid (ICS) used for the treatment of persistent asthma in patients aged >or= 12 years. MF-DPI has low systemic bioavailability and high glucocorticoid receptor affinity compared with most other ICSs and modifies inflammatory mediators involved in the pathogenesis of asthma. MF-DPI, unlike other available ICSs, is approved for initiation as a once-daily in the afternoon (q.d. PM) regimen. Studies show that MF-DPI 200 or 400 microg q.d. PM treatment significantly improves lung function and symptom control in patients with mild, moderate or severe asthma. MF-DPI 400 microg q.d. PM is reported to be equivalent to fluticasone propionate 250 microg b.i.d. and beclometasone dipropionate 168 microg b.i.d. and more efficacious than budesonide 400 microg, b.i.d. or q.d. MF-DPI is generally well tolerated, with minimal effects on the hypothalamic-pituitary-adrenal axis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Mometasone furoate, ≥98% (HPLC)
Mometasone furoate, European Pharmacopoeia (EP) Reference Standard
USP
Mometasone furoate, United States Pharmacopeia (USP) Reference Standard